ASX Announcement
22 March 2022

Invex to Present at Upcoming Tech / Biotech Broker Briefing Webinar

Invex Therapeutics Ltd (**Invex**, ASX: **IXC,** or the **Company**) a clinical-stage biopharmaceutical company focused on the development and commercialisation of Presendin™ (sustained release Exenatide) for neurological conditions relating to raised intracranial pressure today announces an upcoming presentation by Dr Tom Duthy, Executive Director of Invex to the Tech/Biotech Broker Briefing on Thursday, 24 March 2022 at 12.20pm AEDT.

Broker Briefing is Australia's premier digital broker and investor platform for leading ASX listed companies with over 6,000 members and 5,000 subscribers. Investors who wish to register for the event can navigate to:

https://zoom.us/webinar/register/7416461300160/WN_qezMXs5iSBe4LEINQm-laA.

Participants will be able to submit questions via the panel throughout the presentation, however, we encourage shareholders and investors to send through questions via email beforehand to info@brokerbriefing.com.

This release dated 22 March 2022 has been authorised for lodgement to ASX by the Board of Directors of Invex Therapeutics and lodged by Narelle Warren, Company Secretary.

ENDS

For more information, please contact:

Company/Investors
Dr Thomas Duthy
Executive Director
tduthy@invextherapeutics.com
+61 402 493 727

Media
Margie Livingston
Ignite Communications
margie@ignitecommunications.com.au
+61 438 661 131

To subscribe to Invex email alerts, please visit www.invextherapeutics.com and follow us on Twitter **@InvexThera_ASX**

About Invex Therapeutics Ltd

Invex is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure, such as Idiopathic Intracranial Hypertension (IIH), acute stroke and traumatic brain injury. Invex has trademarked its repurposed Exenatide as Presendin™. www.invextherapeutics.com.

About Idiopathic Intracranial Hypertension (IIH)

IIH features severely raised intracranial pressure which causes disabling daily headaches and can compress the optic nerve. The usual age of onset is 20-30 years, and it is most common in women who are obese. IIH is a rapidly growing orphan indication: its incidence has increased by more than 350% in the last 10 years.

About Presendin™

Presendin™ is a once per week, sub-cutaneous, sustained release (SR) Exenatide microsphere formulation originally developed by Peptron, Inc. (KOSDAQ: 087010). In September 2021 Invex entered into an exclusive collaboration, manufacturing and supply agreement with Peptron for Presendin™ in IIH for all major markets, with the exception of South Korea.

Exenatide is a small peptide and a synthetic version of the GLP-1 agonist exendin-4, which is currently approved for the treatment of type 2 diabetes. In 2017, Invex received orphan drug designation for Exenatide in IIH from the US Food and Drug Administration and European Medicines Agency.